Abstract
Drug delivery to the eye is challenging for formulation scientists due to physiological barriers that separate the eye from the rest of the body. A variety of ocular disorders demand the development of optimal drug delivery systems for the administration of drugs and therapeutic agents that can overcome barriers that restrict drug bioavailability. SiRNA inhibits the expression of target genes and has immense potential as a biological tool for the therapeutic inhibition of disease causing genes; however, delivery of siRNA to ocular tissue is a challenge. Recent literature suggests that nanoplatforms show great promise in enhancing ophthalmic drug delivery. A drug delivery system involving nanoparticles and siRNA could surpass problems faced in ocular delivery with improved biodistribution and lower toxicity. This review covers recent research in the area of nanocarrier siRNA drug delivery for various ocular disorders.
Keywords: Ocular, drug delivery, siRNA, nanoplatforms, polymers, lipid nanoparticles, proteins, dendrimers.
Current Pharmaceutical Design
Title:Nanoplatforms for Delivery of siRNA to the Eye
Volume: 21 Issue: 31
Author(s): Manjir Sarma Kataki, Bibhuti Bhusan Kakoti, Melanie Jameson, Aum Solanki, Anjali Hirani and Yashwant Pathak
Affiliation:
Keywords: Ocular, drug delivery, siRNA, nanoplatforms, polymers, lipid nanoparticles, proteins, dendrimers.
Abstract: Drug delivery to the eye is challenging for formulation scientists due to physiological barriers that separate the eye from the rest of the body. A variety of ocular disorders demand the development of optimal drug delivery systems for the administration of drugs and therapeutic agents that can overcome barriers that restrict drug bioavailability. SiRNA inhibits the expression of target genes and has immense potential as a biological tool for the therapeutic inhibition of disease causing genes; however, delivery of siRNA to ocular tissue is a challenge. Recent literature suggests that nanoplatforms show great promise in enhancing ophthalmic drug delivery. A drug delivery system involving nanoparticles and siRNA could surpass problems faced in ocular delivery with improved biodistribution and lower toxicity. This review covers recent research in the area of nanocarrier siRNA drug delivery for various ocular disorders.
Export Options
About this article
Cite this article as:
Kataki Sarma Manjir, Kakoti Bhusan Bibhuti, Jameson Melanie, Solanki Aum, Hirani Anjali and Pathak Yashwant, Nanoplatforms for Delivery of siRNA to the Eye, Current Pharmaceutical Design 2015; 21 (31) . https://dx.doi.org/10.2174/138161282131151013191051
DOI https://dx.doi.org/10.2174/138161282131151013191051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Tumor Stroma Manipulation By MSC
Current Drug Targets Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials New Strategy Developments in Brain Tumor Therapy
Current Pharmaceutical Design Antitumor Activity and Structure-Activity Relationship of Diterpenoids with a Dehydroabietyl Skeleton
Combinatorial Chemistry & High Throughput Screening The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets Persistent Current Blockers of Voltage-Gated Sodium Channels: A Clinical Opportunity for Controlling Metastatic Disease
Recent Patents on Anti-Cancer Drug Discovery The Delivery of Biologically Active (Therapeutic) Peptides and Proteins into Cells
Current Medicinal Chemistry Protective Effect of <i>Nerium oleander</i> Distillate and <i>Tarantula cubensis</i> Alcoholic Extract on Cancer Biomarkers in Colon and Liver Tissues of Rats with Experimental Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Radionuclide-Labeled Peptides for Imaging and Treatment of CXCR4- Overexpressing Malignant Tumors
Current Topics in Medicinal Chemistry AKT-pathway Inhibition in Chronic Lymphocytic Leukemia Reveals Response Relationships Defined by TCL1
Current Cancer Drug Targets Resveratrol Counteracts Hypoxia-Induced Gastric Cancer Invasion and EMT through Hedgehog Pathway Suppression
Anti-Cancer Agents in Medicinal Chemistry Sesterterpenoids with Anticancer Activity
Current Medicinal Chemistry Combination Treatment of Glioblastoma by Low-Dose Radiation and Genistein
Current Radiopharmaceuticals Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Toward the Development of Inhibitors Directed against Mammalian DDAH Proteins: Considerations from Homology Modeling of DDAH-2 and DDAH Activity Tracing in Tissue Homogenate
Letters in Drug Design & Discovery Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics P53 Gene Therapy Sensitizes Resistant Breast Cancer Cells to Doxorubicin Chemotherapy
Drug Delivery Letters